Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting Mnks for cancer therapy

Jinqiang Hou1, Frankie Lam, Christopher Proud

  • 1School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Oncotarget
|March 7, 2012
PubMed

Insights

Targeting eukaryotic initiation factor 4E (eIF4E) offers a promising anti-cancer strategy. Inhibiting Mnk kinases, which phosphorylate eIF4E, may effectively combat human cancers with reduced toxicity.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Deregulation of protein synthesis, particularly involving eukaryotic initiation factor 4E (eIF4E), is crucial in human cancer development and progression.
  • eIF4E activity significantly influences tumorigenic pathways like PI3K/Akt/mTOR and Ras/Raf/MEK/ERK.

Purpose of the Study:

  • To explore the therapeutic potential of targeting eIF4E phosphorylation by Mnk1 and Mnk2 as an anti-cancer strategy.
  • To evaluate Mnk inhibitors as a potential non-toxic and effective treatment for human cancers.

Main Methods:

  • Investigated the role of eIF4E phosphorylation at Ser209 by Mnk1/Mnk2, downstream of ERK signaling.
  • Assessed the necessity of this phosphorylation event for oncogenic transformation versus normal development.

Main Results:

  • Phosphorylation of eIF4E by Mnk kinases is essential for oncogenic transformation but dispensable for normal development.
  • Pharmacological inhibition of Mnk kinases presents a potential anti-cancer strategy.

Conclusions:

  • Mnk inhibition is a promising therapeutic avenue for human cancers driven by eIF4E deregulation.
  • The lack of selective Mnk inhibitors has hindered clinical development and target validation.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...